EP Patent

EP1418896A2 — Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation

Assigned to Vivus LLC · Expires 2004-05-19 · 22y expired

What this patent protects

A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as 'as needed' basis, i.e., the drug is administ…

USPTO Abstract

A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as 'as needed' basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP1418896A2
Jurisdiction
EP
Classification
—
Expires
2004-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Vivus LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.